Transfusion Medicine and Patient Blood Management
Transfusion medicine is the science of giving another person's blood components safely, rationally and at the correct moment. Patient blood management is the broader discipline of protecting the patient's own oxygen-carrying capacity, limiting blood loss, and using allogeneic blood only when it adds more benefit than harm.
In O&G, transfusion medicine spans three very different situations:
- The bleeding mother with ectopic pregnancy, miscarriage, antepartum haemorrhage, caesarean haemorrhage or postpartum haemorrhage.
- The anaemic mother who needs diagnosis and iron treatment long before delivery, so she does not enter labour without reserve.
- The fetus or neonate affected by red-cell alloimmunisation, fetal anaemia, fetomaternal haemorrhage, fetal/neonatal alloimmune thrombocytopenia or severe neonatal anaemia.
The Primary goal is not to memorise every local blood-bank form. It is to understand why each component exists, what risk it carries, how compatibility works, why product ratios matter in massive haemorrhage, and why the safest transfusion is often the one prevented by good antenatal care.
First Principle: Blood Is a Bundle of Separable Jobs
Before any threshold or protocol makes sense, anchor on what blood actually is. Blood is a liquid tissue that does several unrelated jobs at once. Red cells carry oxygen. Platelets plug damaged vessel walls. Plasma proteins — above all the clotting factors and fibrinogen — turn that plug into a durable clot. Plasma also carries volume, albumin and immunoglobulins. A single donor unit of whole blood contains all of these together, but they have different shelf lives, different storage temperatures and different risks.
That single biological fact drives the entire discipline. Because the jobs are separable, modern blood services fractionate one donation into components: red-cell concentrate, platelets, fresh frozen plasma and cryoprecipitate. One donor can then treat several recipients, each gets only the function they lack, and each component can be stored at its optimal temperature. The cost is that no single component restores everything — a bleeding woman losing whole blood loses red cells, platelets, factors and fibrinogen simultaneously, so replacing only red cells leaves her unable to clot.
Hold two ideas from the start:
- Transfusion replaces a missing function, not a missing fluid. Ask which job is failing — oxygen delivery, the platelet plug, or the fibrin clot — and give that.
- The safest unit is often the one never needed. Every component carries immune, volume and (small) infectious risk, and red-cell antigens transfused into a young woman can shape her future pregnancies. Preventing anaemia and limiting blood loss are therefore part of transfusion medicine, not separate from it.
Everything that follows — the transfusion decision, the three pillars of patient blood management, compatibility, massive-haemorrhage ratios and fetal transfusion — is built on these two ideas.
The Transfusion Decision
Transfusion is not treatment of a number. It is treatment of inadequate oxygen delivery, inadequate haemostasis, or a predictable near-future risk that cannot be corrected fast enough by safer means.
The decision asks five questions:
| Question | Why it matters |
|---|---|
| What function is missing? | Red cells carry oxygen; plasma supplies coagulation factors; platelets provide surfaces; cryoprecipitate supplies fibrinogen |
| Is the patient bleeding now? | Acute haemorrhage needs resuscitation and source control, not a chronic anaemia threshold |
| Can the deficit be corrected without blood? | Iron, B12, folate, uterotonics, surgery, TXA and PBM may prevent exposure |
| What is the risk of transfusion here? | TACO, TRALI, haemolysis, infection, alloimmunisation and future pregnancy implications |
| What is the system reality? | Availability, transport time, crossmatch delay, emergency release pathways and specialist support |
High-yield chain:
Anaemia reduces reserve -> haemorrhage produces oxygen debt sooner -> transfusion restores oxygen-carrying capacity but adds immune/volume/infectious risk -> PBM aims to reduce both anaemia and unnecessary exposure.
Patient Blood Management: the Three-Pillar Frame
Patient blood management is commonly taught as three pillars.
| Pillar | O&G application | Basic-science logic |
|---|---|---|
| Optimise red-cell mass | Screen and treat iron deficiency, folate/B12 deficiency, haemoglobinopathy and chronic disease anaemia | More haemoglobin means more oxygen reserve before labour, surgery or bleeding |
| Minimise blood loss | Active management of third stage, objective blood-loss measurement, uterotonics, TXA for PPH, surgical haemostasis, cell salvage in selected cases | Less loss means less oxygen debt, less dilution, less coagulopathy |
| Optimise tolerance of anaemia and rational transfusion | Treat symptoms/physiology, avoid reflex transfusion, use restrictive thresholds where appropriate, escalate when unstable | Transfusion is targeted to physiology, not habit |
PBM is not anti-transfusion. It is anti-waste and anti-avoidable-harm. In a woman exsanguinating from uterine atony, blood is lifesaving. In a stable antenatal patient with iron deficiency at 28 weeks, iron treatment is better medicine than waiting until she needs emergency blood.
South African Blood-Service Context
South Africa has structured blood services, donor screening, component processing and haemovigilance through SANBS and WCBS systems. The practical Primary implications are:
- Blood is safe but not risk-free.
- Products are scarce and expensive.
- Documentation, consent and identity checks are clinical safety steps.
- Emergency transfusion can proceed in a life-threatening situation when consent cannot be obtained, but the decision and reason must be documented.
- Local protocols matter because product availability, emergency-release processes and laboratory turnaround vary by facility.
In the South African maternity setting, transfusion medicine also sits inside referral reality. A district hospital may need to start resuscitation, give TXA, use available blood products, apply uterine tamponade and transfer early rather than wait for collapse. The science is the same; the operational risk is different.
Blood Components: What Each Product Gives and Does Not Give
Whole blood is separated into components so the missing function can be replaced more precisely.
| Product | Main function | Does not provide | Major O&G use |
|---|---|---|---|
| Red-cell concentrate | Oxygen-carrying capacity | Platelets, fibrinogen, broad clotting-factor replacement | Acute haemorrhage, severe symptomatic anaemia |
| Platelets | Primary haemostasis and platelet surface for thrombin generation | Red-cell oxygen capacity, fibrinogen | Severe thrombocytopenia with bleeding/procedure, platelet consumption in massive haemorrhage |
| Fresh frozen plasma | Multiple coagulation factors and plasma volume | Platelets; concentrated fibrinogen | Coagulopathy with bleeding, massive haemorrhage protocols |
| Cryoprecipitate | Fibrinogen-rich replacement plus factor VIII, vWF, factor XIII | Red cells, platelets, broad volume support | Hypofibrinogenaemia in PPH/DIC/massive transfusion |
| Fibrinogen concentrate | Targeted fibrinogen where available | Other clotting factors and platelets | Selected fibrinogen-poor obstetric bleeding |
| Albumin/plasma derivatives | Specific protein effect | Red cells and clotting package | Selected non-haemorrhage indications |
| Anti-D immunoglobulin | Passive anti-D to prevent RhD alloimmunisation | Treatment of established fetal anaemia | RhD-negative prophylaxis after sensitising events/delivery when indicated |
The rule is: replace the function being lost. Red cells do not correct DIC. Plasma does not carry much oxygen. Platelets do not fix fibrinogen depletion. Cryoprecipitate does not contract a uterus.
Why Three Different Products Stop Bleeding: Primary and Secondary Haemostasis
To choose between platelets, plasma and cryoprecipitate you must hold the two-stage model of haemostasis. When a vessel is injured, primary haemostasis comes first: platelets stick to exposed subendothelial collagen (bridged by von Willebrand factor) and to each other, forming a soft platelet plug within seconds. This plug is fragile. Secondary haemostasis then runs the coagulation cascade — a chain of plasma enzymes that converges on thrombin, which cleaves soluble fibrinogen into insoluble fibrin. Fibrin strands weave through the platelet plug and crosslink it (via factor XIII) into a stable clot. Finally fibrinolysis slowly dissolves the clot once the vessel heals.
Each component maps onto one stage of this model, which is why they are not interchangeable:
| Stage failing | What it needs | Component | Obstetric example |
|---|---|---|---|
| Primary plug (too few/poor platelets) | Platelets and vWF | Platelets (cryoprecipitate supplies vWF) | Severe thrombocytopenia, dilutional/consumptive loss in massive PPH |
| Cascade (factors depleted/diluted) | Multiple clotting factors | Fresh frozen plasma | DIC, dilution after large-volume resuscitation |
| Final fibrin scaffold (low fibrinogen) | Fibrinogen | Cryoprecipitate or fibrinogen concentrate | Abruption, amniotic fluid embolism, advanced PPH |
| Excess fibrinolysis | Stop clot breakdown | Tranexamic acid (drug, not a product) | Established PPH |
Pregnancy itself shifts this balance toward clotting: clotting-factor and fibrinogen levels rise (a term fibrinogen of 4–6 g/L is normal, roughly double the non-pregnant value) and fibrinolysis is suppressed. The clinical consequence is double-edged. It protects against bleeding at delivery, but it also means a "normal-for-a-non-pregnant-adult" fibrinogen during PPH is actually low for pregnancy and signals a clot scaffold already failing. This is the basic-science reason fibrinogen is followed so closely in obstetric haemorrhage.
Compatibility: the Immunology of Safe Transfusion
A red-cell antigen is a sugar or protein structure displayed on the red-cell membrane. The danger of transfusion is immunological: if the recipient has an antibody against an antigen on the transfused cells, the antibody binds and the cell is destroyed. To predict that, you need two pieces of basic science — how the blood-group genes are inherited, and where the dangerous antibodies come from.
Blood-Group Genetics in One Frame
Each blood-group system is controlled by genes that code for the enzymes or proteins building the membrane antigen. The ABO gene sits on chromosome 9 and codes for glycosyltransferases that add a final sugar onto a common precursor (the H substance). The A allele adds one sugar, the B allele adds another, and the O allele is non-functional, so group O cells carry only the unmodified H substance. Because A and B are co-dominant and O is recessive, an AB parent and an O parent can have A and B children but never an O or AB child — the kind of Mendelian logic that occasionally surfaces in disputed-parentage or fetal-risk reasoning.